Literature DB >> 203532

Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C.

C Grose, P A Brunel.   

Abstract

Cell lines derived from human malignant melanoma tumors are susceptible to infection with varicella-zoster virus (VZV). Within 5 days after inoculation of vesicular fluid, cytopathic changes appeared in melanoma cell monolayer cultures that were incubated at either 36 or 32 degrees C. The VZV isolates at the two temperatures were serially propagated by passage of trypsin-dispersed infected cells. A plaque assay was developed utilizing melanoma cell monolayers overlaid with nutrient medium containing carboxymethylcellulose. By this assay method, the growth cycle of a VZV isolate propagated at 36 degrees C was studied and compared with that of another VZV isolate grown at 32 degrees C. With equivalent infected-cell inocula at a ratio on one inoculum cell to eight uninfected cells, the yield of cell-free virus at an incubation temperature of 32 degrees C was slightly higher than at 36 degrees C, although the peak occurred 60 h, rather than 36 h, postinfection. It was also found that the titer of low-passage VZV propagated at 36 degrees C was 0.5 to 1 log higher when assayed at 32 degrees C rather than at 36 degrees C.

Entities:  

Mesh:

Year:  1978        PMID: 203532      PMCID: PMC414067          DOI: 10.1128/iai.19.1.199-203.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  8 in total

1.  Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster.

Authors:  T H WELLER
Journal:  Proc Soc Exp Biol Med       Date:  1953-06

2.  An improved plaque assay for varicella virus.

Authors:  R Hondo; H Shibuta; M Matumoto
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

3.  Improved yields of cell-free varicella-zoster virus.

Authors:  N J Schmidt; E H Lennette
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

4.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

5.  A useful quantitative semimicromethod for viral plaque assay.

Authors:  B Rager-Zisman; T C Merigan
Journal:  Proc Soc Exp Biol Med       Date:  1973-04

6.  Separation of infectious Varicella-Zoster virus from human embryonic lung fibroblasts.

Authors:  P A Brunell
Journal:  Virology       Date:  1967-04       Impact factor: 3.616

7.  Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

Authors:  T E Carey; T Takahashi; L A Resnick; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

8.  The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro.

Authors:  T H WELLER; H M WITTON; E J BELL
Journal:  J Exp Med       Date:  1958-12-01       Impact factor: 14.307

  8 in total
  67 in total

1.  Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine.

Authors:  T I Ng; Y Shi; H J Huffaker; W Kati; Y Liu; C M Chen; Z Lin; C Maring; W E Kohlbrenner; A Molla
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades.

Authors:  Geoffrey A Peters; Shaun D Tyler; Charles Grose; Alberto Severini; Michael J Gray; Chris Upton; Graham A Tipples
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Generation of a reporter cell line for detection of infectious varicella-zoster virus and its application to antiviral studies.

Authors:  Guan-Qing Wang; Tatsuo Suzutani; Yumiko Yamamoto; Yoshiko Fukui; Naoki Nozawa; D Scott Schmid; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

6.  The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22.

Authors:  T C Heineman; J I Cohen
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles.

Authors:  Johnathan Storlie; John E Carpenter; Wallen Jackson; Charles Grose
Journal:  Virology       Date:  2008-10-26       Impact factor: 3.616

8.  BAG3, a host cochaperone, facilitates varicella-zoster virus replication.

Authors:  Christos A Kyratsous; Saul J Silverstein
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

9.  Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay.

Authors:  Yoshiko Fukui; Keiko Shindoh; Yumiko Yamamoto; Shin Koyano; Isao Kosugi; Toyofumi Yamaguchi; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

10.  Identification of phosphorylated residues on varicella-zoster virus immediate-early protein ORF63.

Authors:  Niklaus H Mueller; Matthew S Walters; Roland A Marcus; Laurie L Graf; Jessica Prenni; Don Gilden; Saul J Silverstein; Randall J Cohrs
Journal:  J Gen Virol       Date:  2010-01-20       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.